Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Genmab AS's operating assets for the quarter that ended in Mar. 2026 was MXN195,745 Mil. Genmab AS's operating liabilities for the quarter that ended in Mar. 2026 was MXN24,218 Mil. Genmab AS's Total Assets for the quarter that ended in Dec. 2025 was MXN231,787 Mil. Therefore, Genmab AS's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.74.
Genmab AS Scaled Net Operating Assets Related Terms
Genmab AS Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Genmab AS's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GMABN vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Genmab AS's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Genmab AS's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.74 mean?
Genmab AS (MEX:GMABN) has a Scaled Net Operating Assets of 0.74 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Genmab AS and its competitors.
Is Genmab AS's Scaled Net Operating Assets too high?
Genmab AS's current Scaled Net Operating Assets is 0.74. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Scaled Net Operating Assets compare to VRTX and REGN?
Genmab AS's Scaled Net Operating Assets of 0.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Genmab AS and its competitors. Genmab AS's current Scaled Net Operating Assets is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Scaled Net Operating Assets is 0.74. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Scaled Net Operating Assets is 0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (MEX:GMABN) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for MEX:GMABN:
Scaled Net Operating Assets: 0.74
GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for MEX:GMABN
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMABN has been successfully added to your 
